Ustekinumab for the treatment of Crohn's disease: can it find its niche?

Research output: Contribution to journalArticlepeer-review

Standard

Ustekinumab for the treatment of Crohn's disease : can it find its niche? / Simon, Ebby G; Ghosh, Subrata; Iacucci, Marietta; Moran, Gordon W.

In: Therapeutic Advances in Gastroenterology, Vol. 9, No. 1, 01.2016, p. 26-36.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{039b1997046a4e56bd4b3e4095aa9558,
title = "Ustekinumab for the treatment of Crohn's disease: can it find its niche?",
abstract = "Crohn's disease is an immune-mediated disease that results in panenteric chronic inflammation in genetically predisposed individuals exposed to an appropriate environment. The past two decades have witnessed the emergence of an important class of drugs known as anti-tumour necrosis factor (TNF) agents in the treatment of Crohn's disease. Unfortunately, the utility of these agents have been hampered by primary and secondary nonresponse in a significant proportion of patients. Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin (IL) 12 and 23, is a novel pharmacotherapy for this patient cohort that offers an out-of-class option. It is approved for use in psoriasis and psoriatic arthritis, and has now been evaluated in phase II trials for moderate-to-severe Crohn's disease. We here review the published literature and describe a potential clinical role for its use in this disease cohort.",
author = "Simon, {Ebby G} and Subrata Ghosh and Marietta Iacucci and Moran, {Gordon W}",
year = "2016",
month = jan,
doi = "10.1177/1756283X15618130",
language = "English",
volume = "9",
pages = "26--36",
journal = "Therapeutic Advances in Gastroenterology",
issn = "1756-283X",
publisher = "SAGE Publications",
number = "1",

}

RIS

TY - JOUR

T1 - Ustekinumab for the treatment of Crohn's disease

T2 - can it find its niche?

AU - Simon, Ebby G

AU - Ghosh, Subrata

AU - Iacucci, Marietta

AU - Moran, Gordon W

PY - 2016/1

Y1 - 2016/1

N2 - Crohn's disease is an immune-mediated disease that results in panenteric chronic inflammation in genetically predisposed individuals exposed to an appropriate environment. The past two decades have witnessed the emergence of an important class of drugs known as anti-tumour necrosis factor (TNF) agents in the treatment of Crohn's disease. Unfortunately, the utility of these agents have been hampered by primary and secondary nonresponse in a significant proportion of patients. Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin (IL) 12 and 23, is a novel pharmacotherapy for this patient cohort that offers an out-of-class option. It is approved for use in psoriasis and psoriatic arthritis, and has now been evaluated in phase II trials for moderate-to-severe Crohn's disease. We here review the published literature and describe a potential clinical role for its use in this disease cohort.

AB - Crohn's disease is an immune-mediated disease that results in panenteric chronic inflammation in genetically predisposed individuals exposed to an appropriate environment. The past two decades have witnessed the emergence of an important class of drugs known as anti-tumour necrosis factor (TNF) agents in the treatment of Crohn's disease. Unfortunately, the utility of these agents have been hampered by primary and secondary nonresponse in a significant proportion of patients. Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin (IL) 12 and 23, is a novel pharmacotherapy for this patient cohort that offers an out-of-class option. It is approved for use in psoriasis and psoriatic arthritis, and has now been evaluated in phase II trials for moderate-to-severe Crohn's disease. We here review the published literature and describe a potential clinical role for its use in this disease cohort.

U2 - 10.1177/1756283X15618130

DO - 10.1177/1756283X15618130

M3 - Article

C2 - 26770265

VL - 9

SP - 26

EP - 36

JO - Therapeutic Advances in Gastroenterology

JF - Therapeutic Advances in Gastroenterology

SN - 1756-283X

IS - 1

ER -